Clinical Trial Update: Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating starting durvalumab after chemoradiation in patients with unresectable stage III non-small cell lung cancer. The study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma | Phase 2 | Status: RECRUITING